153 related articles for article (PubMed ID: 12002767)
21. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
22. A new phenotypic classification of bone marrow plasmacytosis.
Kawano MM; Mihara K; Tsujimoto T; Huang N; Kuramoto A
Int J Hematol; 1995 Jun; 61(4):179-88. PubMed ID: 8547606
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma-initiating cells.
Hosen N
Int J Hematol; 2013 Mar; 97(3):306-12. PubMed ID: 23420183
[TBL] [Abstract][Full Text] [Related]
24. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma.
Pilarski LM; Szczepek AJ; Belch AR
Blood; 1997 Nov; 90(9):3751-9. PubMed ID: 9345062
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD44 isoforms on isolated bone marrow plasma cells and peripheral CD19+ B cells of patients with multiple myeloma and healthy individuals.
Schuster-Kolbe J; Ludwig H; Adolf GR; Heider KH
Leuk Lymphoma; 1999 Jun; 34(1-2):95-103. PubMed ID: 10350336
[TBL] [Abstract][Full Text] [Related]
27. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Caligaris-Cappio F; Bergui L; Tesio L; Pizzolo G; Malavasi F; Chilosi M; Campana D; van Camp B; Janossy G
J Clin Invest; 1985 Sep; 76(3):1243-51. PubMed ID: 2931452
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
29. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.
Yaccoby S; Epstein J
Blood; 1999 Nov; 94(10):3576-82. PubMed ID: 10552969
[TBL] [Abstract][Full Text] [Related]
30. Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
[TBL] [Abstract][Full Text] [Related]
31. Plasma cell morphology in multiple myeloma and related disorders.
Ribourtout B; Zandecki M
Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma.
Yu SC; Chen SU; Lu W; Liu TY; Lin CW
Histopathology; 2011 May; 58(6):896-905. PubMed ID: 21401705
[TBL] [Abstract][Full Text] [Related]
33. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotypic studies of monoclonal gammopathy of undetermined significance.
Olteanu H; Wang HY; Chen W; McKenna RW; Karandikar NJ
BMC Clin Pathol; 2008 Nov; 8():13. PubMed ID: 19040735
[TBL] [Abstract][Full Text] [Related]
35. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
36. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
Yaccoby S
Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
[TBL] [Abstract][Full Text] [Related]
37. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
38. CD32-mediated suppression of plasma cells in patients with multiple myeloma.
Ross B
Haematologica; 2006 Jul; 91(7):869A. PubMed ID: 16818269
[No Abstract] [Full Text] [Related]
39. [Phenotypic analysis of myeloma cells].
Mihara K; Harada H; Kawano MM
Nihon Rinsho; 1995 Mar; 53(3):574-9. PubMed ID: 7699888
[TBL] [Abstract][Full Text] [Related]
40. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
Ely SA; Knowles DM
Am J Pathol; 2002 Apr; 160(4):1293-9. PubMed ID: 11943714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
